Linkedin Youtube
Launch Digital Edition

Webinars and Commercial Conversations — Register Now

Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.

Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace Directory

QuidelOrtho launches certified analyzer program

October 2025—QuidelOrtho Corp. has launched a certified analyzer program designed to expand access to high-quality diagnostic testing in rural and community hospitals across the United States. The program is tailored for clinics, physician office labs, and small hospitals with fewer than 100 beds. Each analyzer in the program undergoes a robust, multipoint certification process at QuidelOrtho’s Rochester, NY, facility. It includes more than 140 system checks, functional adjustments, hardware cleaning or replacement, and extensive performance testing. The program features certified Vitros XT 7600 and 5600 integrated systems and the Vitros 3600 immunodiagnostic system. A 12-month warranty on service and support is included.

Haystack MRD ctDNA test gets breakthrough device designation

October 2025—The Food and Drug Administration has granted breakthrough device designation for Quest Diagnostic’s Haystack MRD circulating tumor DNA test. The test is used for identifying minimal residual disease in patients with stage two colorectal cancer following curative-intent surgical treatment who may benefit from adjuvant therapy in accordance with therapeutic product labeling.

FDA clears assay to detect CTX-M enzymes

October 2025—The FDA has cleared Hardy Diagnostics’ NG-Test CTX-M Multi, an in vitro diagnostic immunoassay for the qualitative detection of CTX-M enzymes (groups 1, 2, 8, 9, and 25) from pure colonies of Enterobacterales suspected of extended-spectrum beta-lactamase production. These enzymes confer resistance to many beta-lactam antibiotics, making infections more difficult to treat. The test delivers results in 15 minutes.

Roche mass spec test categorized as moderate complexity

October 2025—The Food and Drug Administration has categorized Roche’s Ionify 25-Hydroxy Vitamin D total assay as moderate complexity under the Clinical Laboratory Improvement Amendments of 1988. Roche reported that this is the first time a mass-spectrometry-based test has achieved this designation.

Magnified Learning offers consulting, educational services

October 2025—Magnified Learning offers consulting services across the spectrum of health care operations, including supply chain management, revenue cycle optimization, operational excellence, and organizational change management. The company’s approach leverages next-generation Lean Six Sigma, clinical integration strategies, and advanced technology platforms to create a sustainable alignment between operational performance and financial outcomes. Magnified Learning also offers online certification programs that feature sophisticated online learning management systems with self-paced curricula, comprehensive content previews, and embedded assessment tools compatible across all major operating systems. Each certification includes continuous learning pathways and recertification opportunities.

Eppendorf introduces next-generation mechanical pipettes

October 2025—Eppendorf has launched the Eppendorf Research 3 Neo mechanical pipette. Users can choose between two volume settings and speeds. The pipette can be adjusted for different liquid types, tip geometries, and reverse pipetting and a volume lock feature prevents unintentional volume changes. The use of ColorTag marking rings provides color-coded identification.

C2N launches RUO blood tests for Alzheimer’s disease

September 2025—C2N Diagnostics has launched two plasma assays for research use only. C2N eMTBR-tau243 (endogenous microtubule binding region) is a blood test that selectively detects a specific region of tau; this fragment has been shown to closely track insoluble tau aggregates within neurofibrillary tangles in Alzheimer’s disease. The assay builds on the existing C2N eMTBR-tau243 test in cerebrospinal fluid launched by the company nearly two years ago. C2N obtained exclusive rights for these technologies from the Bateman Lab at WashU Medicine, St. Louis, Mo. The company plans to integrate the new plasma C2N eMTBR-tau243 assay into clinical routine in the future.

FDA approves Oncomine Dx Express for Zegfrovy

September 2025—The FDA has approved Thermo Fisher Scientific’s Oncomine Dx Express test, an in vitro diagnostic assay, for use as a companion diagnostic for Dizal’s Zegfrovy (sunvozertinib) to identify patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations. In addition, the test has been approved for tumor profiling in solid tumors and detects cancer mutations with evidence of clinical significance and potential clinical significance across 46 genes.

Bruker MALDI Biotyper systems awarded ACT label

September 2025—Bruker’s MALDI Biotyper Sirius and Sirius One systems have been awarded the My Green Lab ACT Ecolabel. The MALDI Biotyper systems for microbial identification received an Environmental Impact Factor score of 26.8 (EU and U.K.) and 35.4 (United States).

Proscia releases laboratory leadership report

September 2025—Proscia partnered with the Dark Intelligence Group to survey more than 360 senior professionals representing independent, hospital, and academic laboratories and published a report on the findings. The “2025 Laboratory Leadership Report: Insights on Digital Pathology, AI, and Precision Medicine” finds that 38 percent of laboratory leaders cite staffing shortages as their biggest challenge and 31 percent cite declining reimbursement as their top concern. The top-ranked opportunities for labs are automation to drive efficiency (30 percent), molecular and genetic testing (29 percent), and artificial intelligence (25 percent).

MARKETPLACE

TRENDING